CBL0137

CBL0137, a curaxin compound, is a histone chaperone facilitates chromatin transcription (FACT) inhibitor. CBL0137 downregulates NF-κB and activates p53. CBL0137 restores both histone H3 acetylation and trimethylation. CBL0137 is an anticancer agent. CBL0137 induces cancer cell apoptosis[1].

Product Specifications

CAS Number

[1197996-80-7]

Product Name Alternative

Curaxin 137; CBL-C137

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Histone Acetyltransferase; MDM-2/p53; NF-κB

Type

Reference compound

Related Pathways

Apoptosis; Epigenetics; NF-κB

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/CBL-0137.html

Concentration

10mM

Purity

99.73

Solubility

DMSO : 11.11 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CC(NCCN1C2=C(C3=C1C=CC(C(C)=O)=C3)C=C(C(C)=O)C=C2)C

Molecular Formula

C21H24N2O2

Molecular Weight

336.43

Precautions

H302, H315, H319, H335

References & Citations

[1]Barone TA, et al. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma. Neuro Oncol. 2017 Feb 1;19 (2) :186-196. h|[2]Burkhart C, et al. Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer. Oncotarget. 2014 Nov 30;5 (22) :11038-53.|[3]Ehteda A, et al. Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG. Cell Rep. 2021 Apr 13;35 (2) :108994.